Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B‐cell lymphoma/leukaemia: a Children's Oncology Group report
Year: 2013
Type: article
Abstract: The ANHL01P1 trial was undertaken to determine pharmacokinetics and safety following the addition of rituximab to French-American-British/Lymphome Malins de Burkitt (FAB/LMB96) chemotherapy in 41 children and adolescents with Stage III/IV mature B-cell lymphoma/leukaemia. Patients received rituximab (375 mg/m(2) ) days -2 and 0 of two induction cycles and day 0 of two consolidation cycles. Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d. Rituximab can be safely added to FAB chemotherapy with high early rituximab peak/trough levels and a long t½.
Source: British Journal of Haematology
DOI: 10.1111/bjh.12434
Institutions: University at Buffalo, State University of New York, Medical City Children's Hospital, University of Utah, University of Hawaiʻi at Mānoa, University of Hawaii System, The Ohio State University, New York Medical College, University of Nebraska Medical Center, Harvard University, Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2017846225